drugset / Trial / NCT01517399
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
SequentialOpen-labelOther
Summary
The purpose of this study is to determine the effects of tivantinib on the pharmacokinetics of omeprazole, s-warfarin, caffein, midazolam, or digoxin in patients with cancer.
Timeline
- Start
- 2011-12
- Primary completion
- 2013-08
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caffeine | Small molecule | 200 mg | Oral |
| Subject | Digoxin | Other / unclassified | 0.25 mg | Oral |
| Subject | Midazolam | Small molecule | 1.5 mg | Intravenous |
| Subject | Omeprazole | Other / unclassified | 40 mg | Oral |
| Subject | S-warfarin | Unknown | 10 mg | Oral |
| Subject | Tivantinib | Small molecule | 120 mg | Oral |